Premium
Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease‐free survival, and clinical endocrine response
Author(s) -
Pertschuk Louis P.,
Eisenberg Karen Byer,
Thelmo William L.,
Cruz Wilhelmina P.,
Feldman Joseph G.,
Carter Anne C.,
Thorpe Susan M.,
Christensen Ib J.,
Rasmussen Birgette B.,
Rose Carsten,
Greene Geoffrey L.
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880715)62:2<342::aid-cncr2820620219>3.0.co;2-1
Subject(s) - medicine , monoclonal antibody , endocrine system , breast cancer , monoclonal , progesterone receptor , receptor , cancer , oncology , antibody , cancer research , hormone , immunology , estrogen receptor
Abstract A new immunocytochemical assay for progesterone receptor (PgR‐ICA) employing the monoclonal antibody JZB 39 was used to study tumors from two series of patients with breast cancer. In Series 1 assay results were in agreement with those of biochemistry in 76% of 338 cases ( P < 0.001) and in 54% of 101 cases in Series 2 ( P < 0.001). Agreement was better in Series 1 because it included fresher, previously untouched specimens. There were 70 patients in Series 1 with known clinical endocrine response. A negative assay correlated with disease progression in 45 of 57 patients, significantly better than with biochemistry ( P = 0.013). In comparing 39 women with rapid disease progression with 39 free of disease at 5.1 years, those with PgR‐ICA‐positive tumors were over four times more likely to remain disease‐free than those with negative results ( P = 0.007). Product moment life‐table analysis of 79 patients from Series 2 showed a significantly better cumulative survival for those with PgR‐ICA‐positive tumors ( P = 0.047). These findings indicate that PgR‐ICA should be of value in planning therapy and predicting disease course in breast cancer patients.